Showing 1641-1650 of 1732 results for "".
- 5 Year Data Show Zeposia Treatment Was Associated with Reduced Brain Volume Loss In Patients with RMShttps://practicalneurology.com/news/5-year-data-reveal-zeposia-treatment-was-associated-with-reduced-brain-volume-loss-in-patients-with-rms/2470586/Results from the phase 3 DAYBREAK open-label extension trial for Zeposia (ozanimod; Bristol Myers Squibb, New York, NY) showed sustained reductions in brain volume loss and consistent safety profiles for up to 5 years of continuous treatment in individuals with relapsing forms of multiple scleros
- Subcutaneous Ocrevus Zunovo Approved as Treatment for Primary Progressive and Relapsing MShttps://practicalneurology.com/news/subcutaneous-ocrevus-zunovo-approved-as-treatment-for-primary-progressive-and-relapsing-ms/2470576/The Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq; Genentech, South San Francisco, CA) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is a subcutaneous formulation of
- Crexont Extended-Release Capsules Approved for Parkinson Diseasehttps://practicalneurology.com/news/crexont-extended-release-capsules-approved-for-parkinson-disease/2470555/The FDA has approved Crexont (carbidopa and levodopa; Amneal Pharmaceuticals, Bridgewater, NJ) extended-release capsules for the treatment of Parkinson disease (PD). Crexont combines immediate-release granules and extended-release pellets as a novel, oral formulation of carbidopa/levodopa, provid
- Wildfire Smoke Exposure Significantly Increases Dementia Riskhttps://practicalneurology.com/news/wildfire-smoke-exposure-significantly-increases-dementia-risk/2470538/Individuals exposed to wildfire smoke were found to have an increased likelihood of developing dementia. While other forms of ambient air pollution were also found to be harmful for brain health, wildfire fine particulate matter (PM2.5) posed a significantly higher risk for the diagnos
- Investigational Therapy for Facioscapulohumeral Muscular Dystrophy Shows Promise According to Avidity Bioscienceshttps://practicalneurology.com/news/investigational-therapy-for-facioscapulohumeral-muscular-dystrophy-shows-promise-according-to-avidity-biosciences/2470511/Initial 4-month results from the phase 1/2 FORTITUDE clinical trial (NCT05747924) reveal that treatment of people with facioscapulohumeral muscular dystrophy (FSHD) using AOC 1020 (delpacibart braxlosiran [del-brax]; Avidity Biosciences, San Diego, CA) is associated with functional improvement an
- FDA Approves Once-Daily Austedo XR for Tardive Dyskinesia and Chorea Associated with Huntington Diseasehttps://practicalneurology.com/news/fda-approves-once-daily-austedo-xr-for-tardive-dyskinesia-and-chorea-associated-with-huntington-disease/2470487/The Food and Drug Administration (FDA) has approved Austedo XR (deutetrabenazine; Teva Neuroscience, Kansas City, MO) extended-release tablets, a new once-daily formulation of Austedo for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease (HD) in adults. Austed
- Diagnostic Tool for Progressive Supranuclear Palsy Receives Fast Track Designation from FDAhttps://practicalneurology.com/news/diagnostic-tool-for-progressive-supranuclear-palsy-receives-fast-track-designation-from-fda/2470473/Aprinoia Therapeutics (Cambridge, MA) announced that the Food and Drug Administration (FDA) has granted Fast Track Designation to APN-1607, a positron emission tomography (PET) imaging tracer, which can be used to detect specific forms of aggregated tau (3R and 4R) in individuals with suspected p
- Deadline Approaching for Grant Submissions to American Epilepsy Society for Fundinghttps://practicalneurology.com/news/deadline-approaching-for-grant-submissions-to-american-epilepsy-society-for-funding/2470431/The American Epilepsy Society (AES) has funding opportunities for established investigators who conduct basic, translational, and clinical research in seizures, epilepsy, and related disorders. The AES encourages applicants to submit proposals by the forthcoming deadline of April 3, 2024. <
- Real-World Study Results Demonstrate Efficacy of Kesimpta Treatment for Reducing Relapse Rates in Multiple Sclerosis Patientshttps://practicalneurology.com/news/real-world-study-results-demonstrate-efficacy-of-kesimpta-treatment-for-reducing-relapse-rates-in-multiple-sclerosis-patients/2470412/Study results presented at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 demonstrated the efficacy of Kesimpta (ofatumumab; Novartis, East Hanover, NJ) treatment for reducing incidence of relapses in a real world sample of multiple scler
- Novel Brain Cytoprotection Combination Therapy Associated with Improved Functional Outcomes in People with Acute Ischemic Strokehttps://practicalneurology.com/news/novel-brain-cytoprotection-combination-therapy-associated-with-improved-functional-outcomes-in-people-with-acute-ischemic-stroke/2470408/The use of Sanbexin (edaravone and dexborneol; Simcere, Nanjing, China) sublingual tablets, a formulation combining edaravone and dexborneol, was found to result in statistically significant improvements in functional outcomes for people with acute ischemic stroke (AIS) compared with placebo. The